The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic markers and tumor gene expression by mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Michael Schweizer
Consulting or Advisory Role - AstraZeneca; FibroGen; Janssen; Pfizer; Sanofi
Research Funding - Ambrx (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Epigenetix (Inst); Immunomedics (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenith Epigenetics (Inst)
 
Li Liu
Employment - Pfizer
Stock and Other Ownership Interests - Bayer; Pfizer
Patents, Royalties, Other Intellectual Property - patent pending; Pfizer patent pending
Travel, Accommodations, Expenses - Pfizer
 
Szu-Yu Tang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Whijae Roh
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Vinicius Bonato
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
Other Relationship - Catalan Program of Ambulatory Medication Comission (CAHMDA)
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Curtis Dunshee
Employment - Arizona Center for Cancer Care
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen Biotech; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Dendreon (Inst); ESSA (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sumitomo Pharma Oncology (Inst)
 
Guillermo de Velasco
Honoraria - Astellas Pharma; BMS; Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - BMS; BMS; Roche
 
Konstantin Penkov
Consulting or Advisory Role - Nektar
Research Funding - AstraZeneca/MedImmune (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst)
 
Claudia Andreu-Vieyra
Employment - Pfizer
Stock and Other Ownership Interests - Johnson & Johnson; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Neelesh Soman
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Begoña Mellado
Consulting or Advisory Role - Amgen (I); Astellas Pharma; AstraZeneca; Bayer; Janssen; Pfizer; Pfizer (I); Roche; Roche (I)
Research Funding - Bayer; Janssen; Roche
Travel, Accommodations, Expenses - Janssen-Cilag; Roche (I)